Assembly Biosciences reported a net loss of $8.8 million for the first quarter ended March 31, 2025. The company's revenue for the quarter was US$9.42 million, representing a 63% increase compared to the first quarter of the previous year, exceeding revenue estimates.
The company confirmed that ongoing clinical studies for four candidates remain on track, with key data expected in 2025. This includes interim Phase 1b data for the long-acting helicase-primase inhibitors ABI-5366 and ABI-1179, anticipated in fall 2025.
New data from multiple programs were highlighted at various scientific conferences, including ICAR, ESCMID, and EASL 2025. These presentations underscore the continued progress across Assembly Bio's antiviral portfolio and its focus on addressing significant unmet medical needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.